Biomarkers of inflammation in children with tuberculosis

Authors

  • Виолета (Violeta) Мирчевска (Mirchevska)

Abstract

The aim of this  study was to evaluate  the efficacy of using  appropriate biomarkers of inflammation for diagnosis of tuberculosis in children, monitoring the disease and the effects of the applied  therapy.

Material and methods: In this  study, 60 patients were included and divided into  two groups: control group  of 40 healthy children and a group of 20 children with tuberculosis. The subjects from both  groups were aged from 1 to 15 years, matched by age. The children with tuberculosis were hospitalized for diagnostic and therapeutic treatment. None of them received corticosteroid therapy before treatment. Blood samples from patients with tuberculosis were taken  just  before  the therapy and after 2 months. The concentration of three biomarkers close-related with the evolution of the disease was analyzed in blood sera: tumor necrosis factor alpha (TNF-α), C-reactive  protein  (CRP) and procalcitonin (PCT). Serum  concentrations of TNF-a were  measured  in  vitro using IMMULITE 1000 analyzer  for quantitative measurement of TNF-α in serum  (EIA). Determination of CRP and PCT in serum  was done with the quantitative method (ELFA) using i-CHROMA - immune analyzer.

Results: A statistically significant difference was found in the concentrations of TNFa serum before and after treatment  (18.54 ± 1.94  v.s. 10.02± 0.640 pg/ml, p<0.05), СRP before  and after therapy (99.59 ± 9.23 v.s 9.13 ± 1.13 mg/L,  p<0.05), and РСТ (0.31 ± 0.02 v.s. 0.04 ± 0,01 ng/ml, p<0.05).  

Conclusion: The results showed that tested biomarkers of inflammation are important for early diagnosis and monitoring the effects of the anti-tuberculosis therapy.

Downloads

Download data is not yet available.

References

World Health Organization. Global Tuberculosis Control:

Surveillance, Planning, Financing. Geneva: World

Health Organization; 2002.

Casarini M, Aneglio F, Alemanno L. Cytokine levels correlate

with a Radiologic Score in Active Pulmonary Tuberculosis.

Am J Respir Crit Care Med. 1999; 159: 143-148.

American Thoracic Society. Diagnostic Standard and

Classification of Tuberculosis in Adult and Children.

Am Respir Crit Care Med. 2000; 161:1376-1395.

Andersen P, Munk ME, Doherty TM, еt al. Specific immune-

based diagnosis of tuberculosis. Lancet. 2000;

:1099-104.

Alatas F, Alatas O, Metintas M. The rule of IL-12, IL-

, TNFa, IFN- gama and TGF- betaA1 in pulmonary

tuberculosis. Turkish Thoracic Society. 2002; 3

(Suppl. 1):20-23

Toossi Z. The inflammatory response in Mycobacterium

tuberculosis infection. Arch Immunol Ther Exp.

; 48(6): 513-9.

Gerbeaux J. Tuberculose primaire de L enfant. Rev Tuberc.

; 35:315.

WHO. Global tuberculosis control:Survillance, Planning,

Financing. Genova : World Health Organization;

Roach DR, Briscoe H. Tumor necrosis factor (TNF)

and a TNF-mimetic peptide modulate the granulomatous

response to Mycobacterium bovis BCG infection

in vivo. Infect Immun. 1999; 67(10): 5473-6.

Che L, Lu J. Meаsurement of serum tumor necrosis

factor-alfa and interleukin-8 in children with low respiratory

tract infection (LRTI) caused by Mycoplazma

pneumonia. ECACI. 1999; (1): 50-2.

Comstock G. The International Tuberculosis Campaign:

a pioneering venture in mass vaccination and research.

Clin Infect Dis. 1994. 19 (3): 528–540.

Marais BJ, Gie RP, Hesseling AC, et al. A refined symptom-

based approach to diagnose pulmonary tuberculosis

in children. Pediatrics. 2006; 118:1350-9.

Marais BJ, Pai M. Recent advances in the diagnosis of

childhood tuberculosis. Arch Dis Child. 2007; 92: 446-52.

Kapotis C, Samara E. Determination of IL-4, IL-6, IL-8

interleukins and TNF a in patients with tuberculosis

during treatment. DMBS. 2003; (Suppl 2) : 22-23 .

Knoring VE, Simbertsev AS. Changes in the production

of interleukin-1beta, tumor necrosis factor- alfa

and interleukin-2 in relation to the immunity

in patients with pulmonary tuberculosis. Probl Tuberk.

; 4: 31-5.

Beutler B, Krochin N. Control of cachectin/tumor necrosis

factor. Science. 1986; 232: 977- 80.

Schlag G, Redl H. Mediators of Injury and inflammation.

World J Surg. 1996; 20: 406- 410

Schiffman G. Tuberculosis Symptoms. Medicine Health;

Gerbeaux J, Hanoteau J. Medications recentes dans le

traiment de la tuberculose primaire. Rev Tuberc.

; 35:315

Lebel H.M, Bishara J. Dexamethasone therapy for bacterial

meningitis. N Engl J Med. 1988; 319: 964-71.

Lambert H. The Chemioprophylaxis of Tuberculosis.

Amer Rev Resp Dis. 1959; 80:648

Keane J, Gershon S, Wise RP. Tuberculosis associated

with infliximab, a tumor necrosis factor alfa-neutralizing

agent. N Engl J Med. 2001; 345(15):1098-104.

Mitrevski A. Using protein as a marker for inflammation

and sepsis. Mac.Med.Review. 2005; 12: 25-26.

National Institute for Health and Clinical Excellence.

Tuberculosis: Clinical Diagnosis and Management of

Tuberculosis and Measures for Its Prevention and

Control.Clinical guideline 117. 2011.

Barnes FP, Fong SJ, Brennan JP. Local production

of tumor necrosis factor and IFN-g in tuberculous

pleuritis. The Journal of Immunology. 1990;145:

- 154.

Casarini M, Aneglio F, Alemanno L. Cytokine levels

correlate with a radiologic score in active pulmonary

tuberculosis. Am J Respir Crit Care Med. 1999; 159:

-148

Pivet A, Chedevergne FM. Cytokine transcripts in pediatric

tuberculosis: a study with bronchoalveolar

cells. Tuber Lung Dis. 2000; 80(6): 249-58.

Sester M et al. Interferon-� release assays for the diagnosis

of active tuberculosis: a systematic review and

meta-analysis. The European Respiratory Journal.

; 37: 100–11.

Johnston W, Saltzman H, Bufkin J, Smith D. The Tuberculin

Test and the Diagnosis of Clinical Tuberculosis.

Amer Rev Resp Dis. 1960; 81: 189.

Wilson CB, Lewis DB. Basis and implications of selectively

diminished cytokine production in neonatal

susceptibility to infection. Rev Infect Dis.

;12: 410-20.

Al-Nawas B. Krammer I. Shah PM. Procalcitonin in

diagnosis of severe infections. Bur J Med Res. 1996;

(7): 331-3.

Atanasova V. Rosmanova R. Andreeva H. Procalcitonin:

an inovative marker for bacterial infections.Biochemical,

immunologieal and clinical aspects. Clin

AppI Immunol Invest. 2001; 1: 153-60.

Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011; 378:

–72.

Ahmed N, Hasnain S. Molecular epidemiology of tuberculosis

in India: Moving forward with a systems

biology approach. Tuberculosis. 2011; 91: 407–413.

Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis

in children. Lancet Infect Dis. 2003; 3: 624-31.

Vol.7 No.1 2015

Published

2017-07-01

How to Cite

1.
Мирчевска (Mirchevska) Виолета (Violeta). Biomarkers of inflammation in children with tuberculosis. Arch Pub Health [Internet]. 2017 Jul. 1 [cited 2026 Nov. 21];7(1):41-7. Available from: https://journals.mk/index.php/aph/article/view/954